LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
Click on this link for more information.
top of page
bottom of page